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Objectives
To obtain routine clinical practice data on cabazitaxel usage
patterns for patients with metastatic castration-resistant
prostate cancer (mCRPC) and to describe physician-assessed
cabazitaxel effectiveness, health-related quality of life
(HRQoL) and safety.
Patients and Methods
CAPRISTANA was an international, observational cohort
study examining cabazitaxel use for the treatment of patients
with mCRPC. Effectiveness was assessed by overall survival
(OS), progression-free survival (PFS), time to treatment
failure (TTF) and disease control rate. HRQoL was assessed
using the Functional Assessment of Cancer Therapy-Prostate
questionnaire (FACT-P) and the three-level European Quality
of Life questionnaire (EQ-5D-3L). Safety was assessed by
adverse event (AE) reporting.
Results
A total of 189 patients were treated across 54 centres between
April 2012 and June 2016. At baseline, 58.7% had ≥1
comorbidity, 93.7% had an Eastern Cooperative Oncology
Group performance status ≤1, and 60.1% had a Gleason score at
diagnosis of ≥8. Patients received a median of 6 cabazitaxel
cycles; 84.7% received cabazitaxel as second-line therapy. The
median OS, PFS and TTF were 13.2, 5.6 and 4.4 months,
respectively. Cabazitaxel led to disease control in 52.9% of
patients. HRQoL was maintained (40.3%) or improved (32.2%)
in 72.5% of patients based on total FACT-P scores. Interestingly,
53.6% of patients reported pain improvement and a further
21.2% maintained pain control based on FACT-P prostate
cancer-specific pain scores. The most common treatment-related
grade ≥3 AEs were neutropenia (7.9%) and anaemia (2.1%).
Conclusion
Patients in CAPRISTANA treated with cabazitaxel had
similar disease outcomes and safety profiles compared with
large phase III clinical trials. Most patients had maintained or
improved HRQoL scores; >70% of patients had maintained or
improved pain control.
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Introduction
Prostate cancer is the second most frequently diagnosed
cancer type in men [1]. Although early diagnosis is associated
with better prognosis, patients with metastatic castration-
resistant prostate cancer (mCRPC) typically have poorer
outcomes [2]. Several new treatments have been developed in
the last 7 years including docetaxel, cabazitaxel, abiraterone
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acetate, enzalutamide, sipuleucel-T and radium-223 [3–9].
Cabazitaxel was approved in 2010 as a second-line
chemotherapy in combination with prednisone for treatment
of patients with hormone-refractory metastatic prostate
cancer previously treated with a docetaxel-containing
treatment regimen based on the phase III TROPIC study
[6,9,10]. Cabazitaxel is a next-generation taxane, selected for
testing in clinical trials based on activity in docetaxel-sensitive
and -resistant cell lines [11]. Cabazitaxel also exhibits
stronger suppression of microtubule dynamics, faster cellular
uptake and better intracellular retention than docetaxel
in vitro [12].
Because of the exclusive design of clinical trials, patients
with additional complicating factors, such as comorbidities
and advanced age, are frequently not included. Real-world
studies provide an opportunity to validate the outcomes
reported in large phase III trials using diverse patient
populations and to identify unmet medical needs to better
guide research and improve patient care. These studies help
identify potential treatment risk factors, trends in healthcare
service utilization, disparities in treatment access and health-
related quality of life (HRQoL), and costs associated with
disease management [13].
The TROPIC and PROSELICA randomized clinical trials
demonstrated the efficacy and safety of cabazitaxel; however,
the effectiveness of cabazitaxel and its impact on HRQoL in
routine clinical practice is still unknown.
CAPRISTANA, an international, multicentre, observational,
prospective cohort study examined the use of cabazitaxel in
conjunction with prednisone or prednisolone in routine
clinical practice settings in patients with mCRPC. The
primary objective was to observe the usage patterns of
cabazitaxel; secondary objectives included further description
of cabazitaxel usage patterns (subsequent therapies and use of
granulocyte-colony stimulating factor [G-CSF]), clinical
outcomes (overall survival [OS], progression-free survival
[PFS], time to treatment failure [TTF] and disease control
rate), HRQoL and safety.
Patients and Methods
Study Design and Population
CAPRISTANA was a non-interventional registry study
(CABAZC 06092). Patients with mCRPC were enrolled across
54 centres in Lebanon, Czech Republic, Spain, Austria, Russia
and Bulgaria. To be included in the study patients had to
have a diagnosis of mCRPC, be aged ≥18 years, have received
previous treatment with docetaxel and be scheduled to receive
cabazitaxel as prescribed by their physician. Exclusion criteria
included previous treatment with cabazitaxel or participation
in another clinical study at the time of enrolment. All
patients provided written consent prior to enrolment in the
study, which was reviewed and approved by the appropriate
Ethics Committee.
Data were recorded using an electronic case report form for
≤1.5 years after the first cabazitaxel dose or until death,
whichever occurred first. The same electronic case report
form was used across centres to gather information about
patient and disease characteristics. Data were recorded at
baseline, and every 3 months (15 days) for endpoint
analysis. Baseline data included: patient characteristics (age,
body mass index, Charlson comorbidity index, Gleason
score); disease characteristics (Eastern Cooperative Oncology
Group performance status [ECOG-PS], metastases, time since
diagnosis); and treatment history (lines of prior therapy,
response to docetaxel). Endpoint analyses included patient
status, cabazitaxel usage, G-CSF treatment, associated
therapies, response to cabazitaxel and clinical symptoms.
Use of Cabazitaxel
Patients with mCRPC scheduled to receive cabazitaxel were
prescribed the recommended dose at the time of 25 mg/m2,
administered as a 1-h intravenous infusion every 3 weeks in
combination with oral prednisone or prednisolone 10 mg daily.
Some patients received a starting dose of 20 mg/m2 as directed
by their physician. Patients were allowed G-CSF from cycle 1.
Efficacy Assessments
Overall survival was evaluated from date of first cabazitaxel
administration to date of death from any cause. PFS was
evaluated from the date of first cabazitaxel administration to
the date of disease progression or death from any cause.
Disease progression was defined as tumour or clinical
progression or rising PSA level during or after cabazitaxel
therapy. TTF was evaluated from the date of first
administration of cabazitaxel to the date of cabazitaxel
discontinuation, regardless of the cause. Criteria for response
rate included PSA, clinical symptoms (including pain) and
tumour imaging. Patients were assessed for efficacy at week
12, as recommended by Prostate Cancer Clinical Trials
Working Group 2 guidelines.
Health-related Quality of Life Assessments
Health-related quality of life was assessed based on the results
of the Functional Assessment of Cancer Therapy-Prostate
(FACT-P) and the three-level European Quality of Life (EQ-
5D-3L) questionnaires provided at baseline and every two
cycles until cabazitaxel discontinuation, then every 3 months
until death or 1.5 years after treatment discontinuation.
The FACT-P is a validated multidimensional prostate cancer-
specific patient-reported outcome measure [14]. The
questionnaire consists of five subscales: physical, social,
emotional and functional well-being, and a prostate cancer-
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subscale (PCS). The five subscales are summed to derive the
FACT-P total score, which ranges from a minimum of 0 to a
maximum of 156, with higher values representing better
HRQoL [15,16]. PCS-pain is a pain-related score ranging
from 0 to 16 based on four questions from the FACT-P
questionnaire interrogating pain specifically (P1, P2, P3, GP4)
[14]. Differences in scores were clinically important if there
was a change of 10 points for the FACT-P total score, 3
points for the FACT-P subscales (physical, social, emotional
and functional well-being, and PCS) and 2 points for the
FACT-P PCS-pain score [14].
The EQ-5D-3L is a widely used generic patient-reported
outcome instrument in clinical trials and observational studies
[17,18]. The questionnaire assesses three levels of impairment
in five dimensions of health: mobility; self-care; usual activities;
pain/discomfort; and anxiety/depression, and includes a visual
analogue scale (VAS) [17,18]. EQ-5D-3L scores are converted
into health state utility values using the UK 3L valuation set
(with health state utility value scores ranging from 0.594 to
1.0). The EQ-5D-VAS ‘thermometer’ scores range from 0 to
100, with higher values representing a better health state
[17,18]. Differences in score were clinically important if there
was a change of 7 points on the EQ-5D VAS and 0.074
points for the EQ-5D health state utility value score [19,20].
Safety Assessments
Adverse events (AEs) were collected from the time the
patients signed the informed consent form to 30 days after
the last administration of cabazitaxel. Treatment-emergent
adverse events (TEAEs) were defined as AEs that began,
worsened or became serious between the first administration
of cabazitaxel and 30 days after the last administration of
cabazitaxel during the study. Serious AEs occurring >30 days
after last treatment with cabazitaxel that were considered to
be related to cabazitaxel treatment were also collected.
Statistical Considerations
The analyses of this study were descriptive, and the sample
size was calculated based on 95% CIs associated with event
rate estimations for individual countries to obtain sufficient
data to fulfil post-reimbursement requirements. All
summaries and statistical analyses were generated using SAS
software version 9.2. Time-to-event outcomes were computed
using the Kaplan–Meier estimates (95% CI), and the median
survival times (with 95% CI) were provided.
Results
Patient Characteristics
A total of 191 patients were enrolled in the CAPRISTANA
study, of whom 189 received cabazitaxel between April 2012
and June 2016. Patients had a median age of 69 years
(Table 1). Most patients had an ECOG-PS ≤1 (177 patients;
93.7%), a Gleason score at diagnosis of ≥8 (107 patients;
60.1%) and ≥1 comorbidity at baseline (111 patients; 58.7%).
Most patients had bone metastases (165 patients; 87.3%). The
median time from prostate cancer diagnosis to enrolment was
4.0 years, and 17.0 months from diagnosis of mCRPC to
enrolment. All patients received at least one cycle of docetaxel
before beginning treatment with cabazitaxel. Patients received
a median of 6 docetaxel cycles prior to cabazitaxel, with 114
(60.3%) discontinuing docetaxel in the previous line because
of disease progression. Patients also received non-
chemotherapy-based treatments including 72 (38.1%) who
received prostate cancer surgery, 100 (52.9%) who underwent
radiotherapy and 178 (94.2%) who received some form of
hormonal therapy.
Clinical Use of Cabazitaxel
For the 189 patients who were treated with cabazitaxel, 160
(84.7%) received cabazitaxel as second-line chemotherapy
(Table 2). Patients received a median (range) of 6 (1–24)
cabazitaxel cycles. G-CSF was received by 107 patients
(56.6%) during cycle 1, with 100 patients (52.9%) receiving
prophylactic G-CSF and seven (3.7%) receiving therapeutic
G-CSF.
All patients discontinued cabazitaxel, with 111 (58.7%)
discontinuing as a result of disease progression, 28 (14.8%) at
patient request, and 28 (14.8%) for ‘other’ reasons, i.e.
physician’s direction, end of scheduled treatment or end of
the 1.5-year follow-up period (Table 2). AEs were the least
common reason for patients to discontinue cabazitaxel (22
patients; 11.6%). Dose modifications were required in 103
patients (54.5%), with dose delay being required in 96 of
these patients. Non-AE-related events were the most frequent
(42.9%) reasons for dose delay. Dose reduction was required
in 27 patients (14.3%). After discontinuing cabazitaxel, 74
patients (39.2%) received hormonal therapy and 28 (14.8%)
received chemotherapy.
Efficacy
The median OS was 13.2 months, median PFS was 5.6
months and median TTF was 4.4 months (Fig. 1).
Cabazitaxel led to disease control in 52.9% of patients; of
these, 1.1% achieved complete response, 22.2% achieved
partial response and 29.6% achieved stable disease.
Progressive disease was reported in 39.7% of patients. Efficacy
was not evaluable in 14 patients (7.4%).
Health-related Quality of Life
Of 189 patients, 158 (84%) completed HRQoL
questionnaires. During the course of the study, HRQoL
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remained stable (40.3%) or improved (32.2%) in 72.5% of
patients based on FACT-P total score, and pain improved
for over half of patients (53.6%) based on the PCS-pain
score (Table 3). There were no clinically relevant declines
(≥10) in mean change in FACT-P total and (≥3) subscale
scores (Fig. 2); however, there was a clinically meaningful
decline after cycle 10 for the <10 patients who remained on
treatment (data not shown). There was a trend towards a
clinically important improvement in FACT-P PCS score (≥3)
at cycle 3 and for FACT-P PCS-pain score (≥2) at cycle 8.
Maintenance and improvement of HRQoL was also
supported by the EQ-5D-VAS scores, which did not
show clinically relevant changes (7) from baseline
during the course of treatment until cycles 6, 8 and 10, at
which point clinically important improvements were seen
(Fig. 3).
Safety
Treatment-emergent adverse events of any grade possibly
related to cabazitaxel were reported in 37.6% of patients, and
13.8% of patients experienced TEAEs of grade ≥3 (Table 4).
The most common clinical TEAEs of any grade possibly
related to cabazitaxel were anaemia (10.6%), neutropenia
(9.5%), diarrhoea (8.5%) and asthenia (7.9%). Clinical
neutropenia and anaemia were the most common grade ≥3
TEAEs (7.9% and 2.1%, respectively). Serious TEAEs possibly
related to cabazitaxel were reported in 12.2% of patients, the
most common of which was neutropenia (5.8%).
Table 1 Patient baseline characteristics.
N = 189
Median (range) age, years 69 (47–87)
Age, n (%)
<65 years 55 (29.1)
65–75 years 89 (47.1)
≥75 years 45 (23.8)
Median (range) body mass index, kg/m2 27.65 (16.6–38.7)





Median Charlson Comorbidity Index (range) 4.0 (1–35)
At least one comorbidity, n (%) 111 (58.7)




Median time from prostate cancer diagnosis
to inclusion, years (Q1–Q3)
4.0 (2.1–6.0)
Median time from mCRPC diagnosis to
inclusion, months (Q1–Q3)
17.0 (10–29)
Median time since last progression, months (Q1–Q3) 0.5 (0.2–1.0)
Metastatic sites, n (%)
Bone 165 (87.3)
Regional lymph node 65 (34.4)
Visceral, other soft tissue 42 (22.2)
Other 12 (6.3)
Prior treatment, n (%) 189 (100)
Received at least one prior surgery




Prostatectomy and other 6 (3.2)
Received at least one prior radiotherapy, n (%) 100 (52.9)
Received at least one prior hormonal therapy, n (%) 178 (94.2)
Median number of prior hormonal therapies (range) 2.0 (1.0–8.0)
Received at least one prior chemotherapy, n (%) 189 (100)
Median number of docetaxel cycles (Q1–Q3) 6 (5–10)
Response to last line of docetaxel, n (%)
Complete response 8 (4.2)
Partial response 42 (22.2)
Stable disease 23 (12.2)
Progressive disease 114 (60.3)
Unknown or not evaluable 2 (1.1)
N = 158
Baseline FACT-P scores
Physical well-being, median (Q1–Q3)* 19.9 (16.0–23.0)
Social well-being, median (Q1–Q3)*,† 21.0 (17.0–24.0)
Emotional well-being, median (Q1–Q3)* 15.0 (11.0–18.0)
Functional well-being, median (Q1–Q3)* 15.0 (12.0–19.0)
PCS, median (Q1–Q3)*,§ 27.0 (22.9–32.0)
PCS Pain, median (Q1–Q3)* 8.0 (6.0–12.0)
FACT-P Total, median (Q1–Q3)*,‡ 96.0 (83.0–114.5)
ECOG PS, Eastern Cooperative Oncology Group performance status; FACT-P,
Functional Assessment of Cancer Therapy-Prostate; HRQoL, health-related quality of
life; mCRPC, metastatic castration-resistant prostate cancer; PCS, prostate cancer
subscale; Q1–Q3, quartiles. *Higher values represent better HRQoL. The FACT-P
score scale ranged from 0 to 28 for physical, social and functional well-being, 0–24 for
social well-being, 0–48 for prostate cancer subscale, 0–16 for prostate cancer subscale-
pain, and 0–156 for FACT-P total score. †n = 157. ‡n = 155. §n = 156.
Table 2 Description of cabazitaxel treatment and discontinuation.
Cabazitaxel use during study N = 189





Median duration of exposure, weeks (Q1–Q3) 18.6 (12.0–30.9)
Median number of cycles (Q1–Q3), [range] 6 (4–9), [1–24]
Symptomatic overdose, n (%) 0 (0)
G-CSF use during cycle 1 of cabazitaxel therapy, n (%) 107 (56.6)
Analgesic use associated with cabazitaxel therapy, n (%) 88 (46.6)
At least one dose reduction, n (%) 27 (14.3)
Haematological toxicity 8 (4.2)
Non-haematological toxicity 10 (5.3)
Both haematological and non-haematological toxicity 3 (1.6)
Other reason 7 (3.7)
At least one dose delay, n (%) 96 (50.8)
Haematological toxicity 14 (7.4)
Non-haematological toxicity 7 (3.7)
Both haematological and non-haematological toxicity 1 (0.5)
Other reason 81 (42.9)
Reasons for cabazitaxel discontinuation, n (%)
Progressive disease 111 (58.7)
Patient’s decision 28 (14.8)
Other reason 28 (14.8)
Adverse event 22 (11.6)
Patients receiving treatment after cabazitaxel, n (%)
Chemotherapy 28 (14.8)
Hormonal therapy 74 (39.2)
G-CSF, granulocyte-colony stimulating factor; Q1–Q3, quartiles.
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Discussion
The CAPRISTANA study was a multinational, prospective,
non-interventional study designed to observe the use of
cabazitaxel and evaluate real-world effectiveness, HRQoL
and safety. Patients enrolled in the CAPRISTANA study
were similar to those enrolled in the pivotal phase III trials
of cabazitaxel (TROPIC and PROSELICA). The proportion
of patients with an ECOG-PS ≤1 was similar across all
three studies (CAPRISTANA: 93.7%, TROPIC: 91.9%,
PROSELICA: 89.7%). The presence of bone metastases was
also similar (CAPRISTANA: 87.3%, TROPIC: 83.6%,
PROSELICA: 94.5%). Although patients’ median age in
CAPRISTANA was similar to that in TROPIC, there were
more patients aged ≥75 years in CAPRISTANA (23.8%)
than TROPIC (18.4%) [9,21,22]. The median number of
treatment cycles administered, as well as discontinuation
rates and rationales, TEAEs, rate and type of serious
TEAEs (especially concerning grade ≥3 neutropenia and
anaemia) were similar between CAPRISTANA and the
previous clinical trials [9,21].
Most patients in CAPRISTANA received cabazitaxel as a
second-line therapy as per the labelling instructions; however,
~15% of patients were prescribed cabazitaxel in third or later
100
Median OS:  13.2 months
95% CI: 11.4–16.4
Median PFS:  5.6 months
95% CI: 4.8–6.3
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Fig. 1 Cabazitaxel effect on patient survival and outcome. Response not evaluated in 13 patients and unknown/non-evaluable in one patient. CR,
complete response; NE, non-evaluable; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; RNE, response
not evaluated; SD, stable disease; TTF, time to treatment failure.
Table 3 Health-related quality of life responder analysis by FACT-P
questionnaire subscales and summary score.
Responders, n (%) N = 151*
Improvement Stable Deterioration
Physical well-being 45 (29.8) 50 (33.1) 56 (37.1)
Social well-being† 39 (26.0) 69 (46.0) 42 (28.0)
Emotional well-being 51 (33.8) 52 (34.4) 48 (31.8)
Functional well-being 45 (29.8) 46 (30.5) 60 (39.7)
PCS† 75 (50.0) 30 (20.0) 45 (30.0)
PCS-pain score 81 (53.6) 32 (21.2) 38 (25.2)
FACT-P total‡ 48 (32.2) 60 (40.3) 41 (27.5)
FACT-P, Functional Assessment of Cancer Therapy-Prostate; PCS, prostate cancer
subscale; *Evaluable patients. †n = 150. ‡n = 149.
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Fig. 2 Change in mean Functional Assessment of Cancer Therapy-Prostate questionnaire ( FACT-P) total and subscale scores from baseline with
cabazitaxel over time. Red lines at 10 for total score, 3 for physical, social, emotional and functional well-being subscales and prostate-cancer
subscale (PCS) and 2 for PCS-pain subscale indicate limits of clinically important changes [14]. Positive changes indicate improvement in health-
related quality of life, negative changes indicate deterioration.
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lines of therapy. Most patients discontinued cabazitaxel
because of disease progression (58.7%); only 11.6%
discontinued because of AEs. This contrasts with the TROPIC
trial, where 47.6% discontinued treatment because of disease
progression and 17.7% as a result of AEs [9]. In
CAPRISTANA, patients more often received hormonal
therapies (39.2%) after cabazitaxel treatment than
chemotherapy rechallenge (14.8%). Investigation into patient
outcomes after these additional therapies is warranted because
optimal treatment sequences are still unknown.
Patients enrolled in CAPRISTANA had similar clinical
response rates to cabazitaxel as those included in TROPIC
and PROSELICA [9,19]. The median OS was 13.2 months in
CAPRISTANA, which was similar to that reported in
TROPIC (15.1 months) and in PROSELICA (14.5 months)
[9,19]. In CAPRISTANA, the best overall response was
complete response in 1.1% and partial response in 22.2% of
patients; in PROSELICA, 0.4% and 23.0% had complete
response and partial response, respectively. Because of
differences in how progression was measured, this result
cannot be compared with TROPIC or PROSELICA.
The HRQoL improvements were maintained or improved in
72.5% of patients based on the FACT-P total score and pain
improved in over half of patients based on the FACT-P PCS-
pain score, with most patients reporting improvements within
the first 10 cycles of treatment. In TROPIC, 9.2% of patients
had a pain response associated with cabazitaxel, compared
with 7.7% of patients who received mitoxantrone, although
this was not significantly different (P = 0.63), as assessed by
the Present Pain Intensity score on the McGill-Melzack scale
[19,23]. The Present Pain Intensity score was also used in a
Swiss registry study observing patients in the routine clinical
practice setting [24]. In CAPRISTANA, 53.6% reported pain
improvement and a further 21.2% maintained pain control, as
determined by FACT-P PCS-pain score. To our knowledge,
this is the first report of maintained or improved pain control
based on FACT-P PCS-pain score for cabazitaxel treatment in
patients with mCRPC in routine clinical practice.
No new safety concerns were identified; patient toxicity
profiles were similar to previous reports. Previously, the
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Fig. 3 Change in EQ-5D-visual analogue scale (VAS) score from baseline with cabazitaxel over time. Red lines at 7 indicate limits of clinically important
changes; clinically important changes were reported at cycles 6, 8 and 10 (mean changes of 8.5, 8.4 and 7.3, respectively) [19,20]. Positive changes
indicate improvement in health-related quality of life, negative changes indicate deterioration. *Decline in EQ-5D-VAS score from baseline for cycle 7
may be a result of a low number of patients providing feedback.
Table 4 Possibly related treatment-emergent adverse events.
N = 189
All grades Grade ≥3
Possibly related TEAEs occurring in ≥2% of patients, n (%)
Any class 71 (37.6) 26 (13.8)
Anaemia 20 (10.6) 4 (2.1)
Neutropenia 18 (9.5) 15 (7.9)
Diarrhoea 16 (8.5) 2 (1.1)
Asthenia 15 (7.9) 1 (0.5)
Nausea 10 (5.3) 1 (0.5)
Fatigue 10 (5.3) 0
Decreased appetite 9 (4.8) 0
Vomiting 7 (3.7) 2 (1.1)
Constipation 4 (2.1) 0
Stomatitis 4 (2.1) 0
Peripheral neuropathy 4 (2.1) 0
Possibly related serious TEAEs occurring in ≥2% of patients, n (%)
Any class 23 (12.2) 17 (9.0)
Neutropenia 11 (5.8) 9 (4.8)
Diarrhoea 5 (2.6) 2 (1.1)
Anaemia 4 (2.1) 3 (1.6)
TEAE, treatment-emergent adverse event.
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phase III trials was based on laboratory assessments, and was
82% in TROPIC and 73.3% in PROSELICA [9,19]. Similarly,
the rates of laboratory grade ≥3 anaemia were 11% and 14%
in TROPIC and PROSELICA, respectively. In CAPRISTANA,
neutropenia and anaemia rates were only recorded based on
symptomatic, clinical AEs (as opposed to laboratory
assessments), incidences of which were similar to those
recorded in the clinical trials. The rates of possibly related
grade ≥3 clinical neutropenia were 7.9% in CAPRISTANA,
21.3% in TROPIC and 9.6% in PROSELICA. Similarly, the
rates of possibly related grade ≥3 clinical anaemia were 2.1%
in CAPRISTANA, 2.7% in TROPIC and 2.4% in PROSELICA
(Sanofi; data on file). G-CSF use was permitted in
PROSELICA, but avoided during the first cycle, and no
restrictions were applied in CAPRISTANA. The question of
whether early prophylactic use of G-CSF may help reduce
neutropenia rates associated with cabazitaxel administration
merits further study.
Limitations of the present study include variability among the
sites regarding use of electronic record forms, which could
potentially lead to missing data and incomplete representation
of cabazitaxel use in the clinical setting. There were also 14
patients who were not evaluable for efficacy. Additionally, only
nine patients received >10 cycles of cabazitaxel; consequently,
results after cycle 10 must be interpreted with caution.
In summary, cabazitaxel was predominately used as a second-
line chemotherapy, with patients receiving a median of 6
cycles. Patients enrolled in CAPRISTANA had similar disease
outcomes compared with patients in TROPIC and
PROSECLICA, which supports the effectiveness and safety of
cabazitaxel for patients with mCRPC. Results of the study
also show maintenance or improvement in HRQoL in the
majority of patients and reduction of pain in over half of
patients. These real-world data help to better understand the
effectiveness of cabazitaxel and its impact on mCRPC-related
HRQoL and pain in a routine clinical setting.
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